Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: Role of nitric oxide

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 6, 2012, Pages

  Aytekin, Metin ^a   Aulak, Kulwant S ^a   Haserodt, Sarah ^a   Chakravarti, Ritu ^a   Cody, Joseph ^a   Minai, Omar A ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

L NAME; Nitric oxide synthases; TRAP

Indexed keywords

ADENOSINE DIPHOSPHATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBIN RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOSIS; VASOCONSTRICTION;

ADENOSINE DIPHOSPHATE; ADULT; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET COUNT; PULMONARY ARTERY; VASOCONSTRICTION;

EID: 84858167673     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00289.2011     Document Type: Article

References (44)

1. Berkels R, Bertsch A, Zuther T, Dhein S, Stockklauser K, Rosen P, Rosen R. Evidence for a NO synthase in porcine platelets which is stimulated during activation/aggregation. Eur J Haematol 58: 307-313, 1997.
2. Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol 27: 154-158, 1996.
3. Chen LY, Mehta JL. Variable effects of L-arginine analogs on L-arginine- nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther 276: 253-257, 1996.
4. De Marco T. Pulmonary arterial hypertension and women. Cardiol Rev 14: 312-318, 2006.
5. Dweik RA. Nitric oxide production in the lung and its regulation by oxygen. In: Disease Markers in Exhaled Breath: Basic Mechanisms and Clinical Applications (NATO Science Series), edited by Marczin N, Yacoub MH. Amsterdam, The Netherlands: IOS, 2002, p. 11-17.
6. Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, Kavuru M, Hammel J, Abu-Soud HM, Erzurum SC. NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci USA 98: 2622-2627, 2001.
7. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82: 841-847, 1990.
8. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 90: 863-871, 2003.
9. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-356, 1997.
10. Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 445-451, 2005.
11. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580-587, 1984.
12. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Muller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NOindependent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 6: 1376-1384, 2008.
13. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med 70, Suppl 1: S2-8, 2003.
14. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95: 2514-2522, 2000.
15. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 22: 451-458, 2001.
16. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
17. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, Thomassen MJ, Erzurum SC. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 158: 917-923, 1998.
18. Kaul S, Waack BJ, Padgett RC, Brooks RM, Heistad DD. Interaction of human platelets and leukocytes in modulation of vascular tone. Am J Physiol Heart Circ Physiol 266: H1706-H1714, 1994.
19. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 128: 2355-2362, 2005.
20. Laufs U, Liao JK. Posttranscriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
21. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 278: 30725-30731, 2003.
22. Lopes AA, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Respir J 8: 530 -536, 1995.
23. Lopes AA, Maeda NY, Almeida A, Jaeger R, Ebaid M, Chamone DF. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 44: 701-706, 1993.
24. Maclean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 661: 309-322, 2010.
25. Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194: 960-965, 1993.
26. Marcondes S, Cardoso MH, Morganti RP, Thomazzi SM, Lilla S, Murad F, De Nucci G, Antunes E. Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration. Proc Natl Acad Sci USA 103: 3434-3439, 2006.
27. Marjanovic JA, Stojanovic A, Brovkovych VM, Skidgel RA, Du X. Signaling-mediated functional activation of inducible nitric-oxide synthase and its role in stimulating platelet activation. J Biol Chem 283: 28827-28834, 2008.
28. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 114: 1417-1431, 2006.
29. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125: 370-377, 1995.
30. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3=,5=- monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57: 946 -955, 1981.
31. Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM, 3rd Faraday N, Lowenstein CJ. Regulation of platelet granule exocytosis by Snitrosylation. Proc Natl Acad Sci USA 102: 3782-3787, 2005.
32. Naseem KM, Riba R. Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 6: 10-19, 2008.
33. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915-918, 1994.
34. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
35. Pena E, Padro T, Molins B, Vilahur G, Badimon L. Proteomic signature of thrombin-activated platelets after in vivo nitric oxide-donor treatment: coordinated inhibition of signaling (phosphatidylinositol 3-kinasegamma, 14-3-3zeta, and growth factor receptor-bound protein 2) and cytoskeleton protein translocation. Arterioscler Thromb Vasc Biol 31: 2560-2569, 2011.
36. Pietra G. The Pathology of Pulmonary Hypertension. New York: Marcel Dekker, 1997.
37. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 92: 181-187, 1987.
38. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87: 5193-5197, 1990.
39. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW. Primary pulmonary hypertension A national prospective study. Ann Intern Med 107: 216-223, 1987.
40. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57: 2049-2055, 1995.
41. Saxon A. Letter: Inhibition of platelet function by nitroprusside. N Engl J Med 295: 281-282, 1976.
42. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 279: 412-419, 2000.
43. Stuart MJ, Murphy S, Oski FA. A simple nonradioisotope technic for the determination of platelet life-span. N Engl J Med 292: 1310-1313, 1975.
44. Veyradier A, Nishikubo T, Humbert M, Wolf M, Sitbon O, Simonneau G, Girma JP, Meyer D. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 102: 2460-2462, 2000.